Literature DB >> 11342427

Mimicry between neurokinin-1 and fibronectin may explain the transport and stability of increased substance P immunoreactivity in patients with bone marrow fibrosis.

P Rameshwar1, D D Joshi, P Yadav, J Qian, P Gascon, V T Chang, D Anjaria, J S Harrison, X Song.   

Abstract

Bone marrow (BM) fibrosis may occur in myeloproliferative diseases, lymphoma, myelodysplastic syndrome, myeloma, and infectious diseases. In this study, the role of substance P (SP), a peptide with pleiotropic functions, was examined. Some of its functions-angiogenesis, fibroblast proliferation, and stimulation of BM progenitors-are amenable to inducing BM fibrosis. Indeed, a significant increase was found in SP-immunoreactivity (SP-IR) in the sera of patients with BM fibrosis (n = 44) compared with the sera of patients with hematologic disorders and no histologic evidence of fibrosis (n = 46) (140 +/-12 vs 18 +/-3; P <.01). Immunoprecipitation of sera SP indicated that this peptide exists in the form of a complex with other molecule(s). It was, therefore, hypothesized that SP might be complexed with NK-1, its natural receptor, or with a molecule homologous to NK-1. To address this, 3 cDNA libraries were screened that were constructed from pooled BM stroma or mononuclear cells with an NK-1 cDNA probe. A partial clone (clone 1) was retrieved that was 97% homologous to the ED-A region of fibronectin (FN). Furthermore, sequence analyses indicated that clone 1 shared significant homology with exon 5 of NK-1. Immunoprecipitation and Western blot analysis indicated co-migration of SP and FN in 27 of 31 patients with BM fibrosis. Computer-assisted molecular modeling suggested that similar secondary structural features between FN and NK-1 and the relative electrostatic charge might explain a complex formed between FN (negative) and SP (positive). This study suggests that SP may be implicated in the pathophysiology of myelofibrosis, though its role would have to be substantiated in future research. (Blood. 2001;97:3025-3031)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342427     DOI: 10.1182/blood.v97.10.3025

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  A new role of substance P as an injury-inducible messenger for mobilization of CD29(+) stromal-like cells.

Authors:  Hyun Sook Hong; Jungsun Lee; EunAh Lee; Young Sam Kwon; Eunkyung Lee; Woosung Ahn; Mei Hua Jiang; Jae Chan Kim; Youngsook Son
Journal:  Nat Med       Date:  2009-03-08       Impact factor: 53.440

2.  Tachykinins and Neurokinin Receptors in Bone Marrow Functions: Neural-Hematopoietic Link.

Authors:  Tilman E Klassert; Shyam A Patel; Pranela Rameshwar
Journal:  J Receptor Ligand Channel Res       Date:  2010-04-01

Review 3.  The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.

Authors:  Miguel Munoz; Rafael Covenas; Francisco Esteban; Maximino Redondo
Journal:  J Biosci       Date:  2015-06       Impact factor: 1.826

4.  Aspirin-Mediated Reset of Preeclamptic Placental Stem Cell Transcriptome - Implication for Stabilized Placental Function.

Authors:  Matthew P Romagano; Lauren S Sherman; Bobak Shadpoor; Markos El-Far; Sami Souayah; Sri Harika Pamarthi; Joshua Kra; Anupama Hood-Nehra; Jean-Pierre Etchegaray; Shauna F Williams; Pranela Rameshwar
Journal:  Stem Cell Rev Rep       Date:  2022-07-31       Impact factor: 6.692

5.  Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists.

Authors:  A Molinos-Quintana; P Trujillo-Hacha; J I Piruat; J A Bejarano-García; E García-Guerrero; J A Pérez-Simón; Miguel Muñoz
Journal:  Invest New Drugs       Date:  2018-05-02       Impact factor: 3.850

Review 6.  Neuropeptide substance P and the immune response.

Authors:  Alireza Mashaghi; Anna Marmalidou; Mohsen Tehrani; Peter M Grace; Charalabos Pothoulakis; Reza Dana
Journal:  Cell Mol Life Sci       Date:  2016-06-17       Impact factor: 9.261

7.  Substance P enhances the therapeutic effect of MSCs by modulating their angiogenic potential.

Authors:  Hyun Sook Hong; Suna Kim; Yinji Jin; Youngsook Son
Journal:  J Cell Mol Med       Date:  2020-09-28       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.